Brian Contos and Megan Tooley, Cardiovascular Roundtable
On behalf of the Cardiovascular Roundtable, we are excited to share early results from our analysis of transcatheter aortic valve replacement (TAVR) cases from the just-released Medicare claims data for the 2012 fiscal year (Oct. 1, 2011 – Sept. 30, 2012). To the best of our knowledge, ours is the first analysis of all U.S. TAVR procedures performed in the year following FDA approval.
These analyses address a number of questions we’ve received from members regarding the TAVR marketplace and experiences from early adopters, including volumes, patient characteristics, clinical outcomes, and reimbursement.
New transcatheter valve benchmarks you won't find anywhere else
Megan Tooley, Cardiovascular Roundtable
The decision to pursue transcatheter aortic valve replacement (TAVR) should not be taken lightly—we’ve been helping walk members through the considerations in our recent publication Blueprint for Valve Centers, executive summary webconference, and recent coverage in Cardiovascular Rounds.
But for some progressive institutions, TAVR is the right choice both to fill a clinical need in the community, as well as grow the CV program. So once you’ve made that decision, where do you go from there?
For a quick primer on the top investments to consider when starting a program, we turned to CV leaders at Exempla Saint Joseph Hospital, a 384-bed hospital in Denver, Colorado, who successfully launched a TAVR program last fall.
Read on for three key pieces of advice Saint Joseph Hospital has for institutions looking to launch their own TAVR program.
You've decided to launch a TAVR program...now what?
Nicole MacMillan, Cardiovascular Roundtable
Recently, a new treatment for drug-resistant hypertension known as renal denervation (RDN) has been a hot topic in the CV world. Also known as renal nerve ablation, the procedure has enormous potential to improve treatment for a large portion of the more than 68 million hypertensive patients in the United States, and may have a similarly dramatic impact for CV programs once it's approved by the FDA.
Why the hype surrounding renal denervation?